drugset / Trial / NCT06595355

Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin

NCT06595355

Phase 2/3 Recruiting 52 enrolled Isfahan University of Medical Sciences
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema. A blind study and a randomized and controlled clinical trial are conducted on diabetic patients with macular edema. The patients are divided into two intervention groups (bevacizumab + curcumin) and control (bevacizumab + placebo). The evaluation of the central thickness of the macula and the evaluation of the central volume of the macula are the primary goals and the evaluation of the best visual acuity of the patient is the secondary goal.

Timeline

Start
2021-10-10
Primary completion
2025-09-22
Completion
2025-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 40 mg Oral
Background Bevacizumab Monoclonal antibody 1.25 mg Intravitreal